In this episode, we take a deep dive into the findings from a recent Forbeck Forum on Cell Death in Cancer Therapy, chaired by Kristopher Sarosiek, PhD (Harvard) and Cristina Muñoz-Pinedo, PhD (IDIBELL).

The discussion explores—in accessible, lay-friendly terms—how cancer treatments ultimately work by killing cancer cells, and why understanding the differences between cancer cell death and normal cell death is crucial for improving therapies. Drs. Sarosiek and Muñoz-Pinedo explained how various treatments trigger cell death, how the immune system can be activated or suppressed depending on the type of cell death, and why minimizing collateral damage to healthy tissues remains a central challenge.

The conversation also covers:

• How the immune system recognizes dying cancer cells and why certain forms of cell death can “wake up” immune responses.
• Why some healthy cells can recover from therapy while others—like heart cells—cannot.
• Why cancer cells sometimes hide in specific niches, such as the bone marrow or low-oxygen (hypoxic) regions, and how this affects treatment resistance and relapse.
• Key themes from the meeting’s sessions, including immunogenic cell death, balancing tumor vs. healthy tissue toxicity, and uniting clinicians, basic researchers, and industry scientists.
• The growing intersection of immunology and cancer biology, and how new forms of therapy rely on understanding this relationship.

Overall, the episode offers an insightful look at how researchers are rethinking cancer therapy by focusing not only on killing cancer cells, but on controlling how cells die—and how the immune system responds.